Summary
11.41 0.24(2.10%)05/17/2024
Nevro Corp (NVRO)
Nevro Corp (NVRO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.50 | 8.88 | -12.05 | -32.93 | -30.50 | -57.98 | -80.97 | -54.23 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 11.53 | |
| Open | 11.19 | |
| High | 11.66 | |
| Low | 11.19 | |
| Volume | 339,155 | |
| Change | 0.39 | |
| Change % | 3.50 | |
| Avg Volume (20 Days) | 522,225 | |
| Volume/Avg Volume (20 Days) Ratio | 0.65 | |
| 52 Week Range | 10.27 - 28.89 | |
| Price vs 52 Week High | -60.09% | |
| Price vs 52 Week Low | 12.27% | |
| Range | 3.04 | |
| Gap Up/Down | -0.22 | |
Fundamentals | ||
| Market Capitalization (Mln) | 395 | |
| EBIDTA | -87,049,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -3.1300 | |
| WallStreet Target Price | 15.37 | |
| Book Value | 7.5920 | |
| Earnings Per Share | -2.2800 | |
| EPS Estimate Current Quarter | -1.0500 | |
| EPS Estimate Next Quarter | -0.6600 | |
| EPS Estimate Current Year | -2.5300 | |
| EPS Estimate Next Year | -2.1500 | |
| Diluted EPS (TTM) | -2.2800 | |
| Revenues | ||
| Profit Marging | -0.1917 | |
| Operating Marging (TTM) | -0.3176 | |
| Return on asset (TTM) | -0.1018 | |
| Return on equity (TTM) | -0.2849 | |
| Revenue TTM | 430,745,984 | |
| Revenue per share TTM | 11.8980 | |
| Quarterly Revenue Growth (YOY) | 0.0580 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 276,367,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6427 | |
| Revenue Enterprise Value | 0.8818 | |
| EBITDA Enterprise Value | -4.7877 | |
| Shares | ||
| Shares Outstanding | 36,728,600 | |
| Shares Float | 35,557,004 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.12 | |
| Insider (%) | 3.19 | |
| Institutions (%) | 106.23 | |
05/09 16:05 EST - prnewswire.com
Nevro to Present at BofA Securities 2024 Healthcare Conference
REDWOOD CITY, Calif. , May 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024.
Nevro to Present at BofA Securities 2024 Healthcare Conference
REDWOOD CITY, Calif. , May 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024.
05/08 13:16 EST - zacks.com
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
05/08 02:01 EST - seekingalpha.com
Nevro Corp. (NVRO) Q1 2024 Earnings Call Transcript
Nevro Corp. (NYSE:NVRO ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and President Rod MacLeod - Chief Financial Officer Conference Call Participants Nathan Treybeck - Wells Fargo Anthony Petrone - Mizuho Carolyn Huszagh - Bank of America Justin Lin - William Blair Bradley Bowers - Mizuho Securities Operator Good afternoon. My name is Audra, and I will be your conference operator today.
Nevro Corp. (NVRO) Q1 2024 Earnings Call Transcript
Nevro Corp. (NYSE:NVRO ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and President Rod MacLeod - Chief Financial Officer Conference Call Participants Nathan Treybeck - Wells Fargo Anthony Petrone - Mizuho Carolyn Huszagh - Bank of America Justin Lin - William Blair Bradley Bowers - Mizuho Securities Operator Good afternoon. My name is Audra, and I will be your conference operator today.
05/07 18:31 EST - zacks.com
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.98 per share a year ago.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.98 per share a year ago.
05/07 16:05 EST - prnewswire.com
Nevro Reports First-Quarter 2024 Financial Results
Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, Calif. , May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results.
Nevro Reports First-Quarter 2024 Financial Results
Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, Calif. , May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results.
04/17 08:30 EST - prnewswire.com
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
REDWOOD CITY, Calif. , April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024.
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
REDWOOD CITY, Calif. , April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024.
03/21 13:36 EST - zacks.com
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
02/29 08:31 EST - zacks.com
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
02/28 16:10 EST - prnewswire.com
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw ("NevroFix™").
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw ("NevroFix™").
02/22 18:21 EST - fool.com
Why Nevro Stock Lagged the Market on Thursday
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
Why Nevro Stock Lagged the Market on Thursday
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
02/22 11:51 EST - zacks.com
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
02/21 23:02 EST - seekingalpha.com
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
02/21 18:21 EST - zacks.com
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.54 per share a year ago.
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.54 per share a year ago.
02/21 16:06 EST - prnewswire.com
Nevro Enters Into Cooperation Agreement With Engaged Capital
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif.
Nevro Enters Into Cooperation Agreement With Engaged Capital
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif.
02/21 16:05 EST - prnewswire.com
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results.
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results.
02/14 11:06 EST - zacks.com
Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/01 16:30 EST - prnewswire.com
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies REDWOOD CITY, Calif. , Feb. 1, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of a consensus statement summarizing recommendations based on outcomes from a December 2022 global, interdisciplinary panel, "Advances in the Management of Painful Diabetic Neuropathy," at the Worldwide Initiative for Diabetes Education (WorldWIDE Diabetes) Virtual Global Summit.
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies REDWOOD CITY, Calif. , Feb. 1, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of a consensus statement summarizing recommendations based on outcomes from a December 2022 global, interdisciplinary panel, "Advances in the Management of Painful Diabetic Neuropathy," at the Worldwide Initiative for Diabetes Education (WorldWIDE Diabetes) Virtual Global Summit.
01/29 16:30 EST - prnewswire.com
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024.
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024.
01/19 11:51 EST - zacks.com
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
01/18 16:15 EST - prnewswire.com
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif. , Jan. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Carelon Healthcare , a healthcare services company dedicated to delivering whole-person care with connected healthcare solutions for better outcomes and experiences, will be publishing a new interventional pain management policy that expands spinal cord stimulation (SCS) coverage for painful diabetic neuropathy (PDN).
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif. , Jan. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Carelon Healthcare , a healthcare services company dedicated to delivering whole-person care with connected healthcare solutions for better outcomes and experiences, will be publishing a new interventional pain management policy that expands spinal cord stimulation (SCS) coverage for painful diabetic neuropathy (PDN).